CI

At a glance

ClinicalIndex Comparison Record
Phase 4Not Yet Recruiting· 148 target
Drug / intervention
Liposomal bupivacaine (LB) +1 moredrug
Likely dose
Liposomal bupivacaine (LB) 10 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07643792
NCT07643792Phase 4Not Yet Recruiting

Fascia Iliaca Block Using Liposomal Bupivacaine for Analgesia After Hip Fracture Surgery: a Randomized Trial

Peking University First Hospital·interventional·Posted Jun 12, 2026·Updated Jun 15, 2026

In Brief

A Phase 4 clinical trial evaluating Liposomal bupivacaine (LB) and Plain bupivacaine for Older Adults and 4 related conditions. Not yet recruiting, targeting 148 participants across 1 site.

Detailed Summary

Older patients with hip fractures often suffer from severe pain. Inadequate analgesia increases the risk of postoperative delirium, myocardial injury, and other complications. Peripheral nerve block is an important component of multimodal analgesia, but conventional local anesthetics (such as plain bupivacaine) provide only approximately 12 hours of analgesic duration, which is far from covering the most painful 72 hours after surgery. Liposomal bupivacaine has a slow-release property, prolonging the analgesic duration up to 72 hours after a single injection. However, its clinical advantages in hip fracture surgery remain controversial. The investigators suppose that, compared with plain bupivacaine alone, preoperative supra-inguinal fascia iliaca block using liposomal bupivacaine combined with plain bupivacaine can further improve analgesia, decrease opioid consumption, and improve postoperative recovery quality within 72 hours in older patients after hip fracture surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 4Not Yet Recruiting
20272028
First PostedJun 12, 2026
Enrollment StartJul 1, 2026
Primary CompletionJun 1, 2028
Study CompletionAug 1, 2028
TodayJul 1, 2026
Enrollment to primary: 1.9 yearsPosted 19 days agoPrimary completion in 1.9 years

Interventions

Liposomal bupivacaine (LB)drug

A single preoperative ultrasound-guided supra-inguinal fascia iliaca block will be perfomed using a mixture of 10 mL of 0.5% plain bupivacaine plus 20 mL of liposomal bupivacaine (266 mg), total volume 30 mL. The injection will be performed after negative aspiration and under real-time ultrasound visualization to ensure proper spread between the fascia iliaca and the iliacus muscle. The block will be performed in the preoperative holding area.

Plain bupivacainedrug

A single preoperative ultrasound-guided supra-inguinal fascia iliaca block will be performed using 30 mL of 0.5% plain bupivacaine (150 mg). The injection will be performed after negative aspiration and under real-time ultrasound visualization to ensure proper spread between the fascia iliaca and the iliacus muscle. The block will be performed in the preoperative holding area.